Literature DB >> 4188114

Phenylbutazone and pulmonary oedema.

M Nevins, S Berque, N Corwin, L Lyon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4188114     DOI: 10.1016/s0140-6736(69)90889-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Letter: diffuse pulmonary disorder caused by oxyphenbutazone.

Authors:  D C Cameron
Journal:  Br Med J       Date:  1975-05-31

2.  Lung changes associated with phenylbutazone treatment.

Authors:  J G Thurston; P Marks; D Trapnell
Journal:  Br Med J       Date:  1976-12-11

Review 3.  Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure.

Authors:  J Feenstra; D E Grobbee; A Mosterd; B H Stricker
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

Review 4.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

Review 5.  Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies.

Authors:  Patompong Ungprasert; Narat Srivali; Charat Thongprayoon
Journal:  Clin Cardiol       Date:  2015-12-31       Impact factor: 2.882

Review 6.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 7.  Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance.

Authors:  A G Johnson; P Seideman; R O Day
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

Review 8.  Nonsteroidal anti-inflammatory drugs and heart failure.

Authors:  Gysèle S Bleumink; Johannes Feenstra; Miriam C J M Sturkenboom; Bruno H Ch Stricker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.